OncoMatch

OncoMatch/Clinical Trials/NCT06249321

mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy

Is NCT06249321 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies mFOLFIRINOX plus IMRT for pancreatic cancer.

Phase 2RecruitingFudan UniversityNCT06249321Data as of Jun 2026Location: China

Treatment: mFOLFIRINOX plus IMRTThe purpose of this study is to evaluate the efficacy of mFOLFIRINOX plus radiotherapy to Patients with CA19-9-normal Advanced Pancreatic Cancer refractory to chemotherapy.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

mFOLFIRINOX plus IMRT

Cancer type

Pancreatic Cancer

Biomarker criteria

Required: FUT3 CA19-9 ≤ 37 U/mL (≤ 37 U/mL)

Baseline serum CA19-9 ≤ 37 U/mL

Required: CEACAM5 CEA ≤ 5.2 ng/mL (≤ 5.2 ng/mL)

CEA≤ 5.2 ng/mL

Required: MUC16 CA125 ≤ 35 U/mL (≤ 35 U/mL)

CA125 ≤ 35 U/mL

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Demographics

Ages ≤ 80

Prior therapy

Min 1 prior line

Must have received: chemotherapy

Patients who are refractory to at least one line of chemotherapy

Cannot have received: radiotherapy

who have not received radiotherapy

Lab requirements

Kidney function

Renal insufficiency or dialysis [excluded]

Adequate organ performance based on laboratory blood tests. Renal insufficiency or dialysis [excluded]

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06249321 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior radiotherapy disqualifies patients from enrollment.

Does this trial require FUT3?

Yes, FUT3 CA19-9 ≤ 37 U/mL is a required biomarker for enrollment.

Does this trial require CEACAM5?

Yes, CEACAM5 CEA ≤ 5.2 ng/mL is a required biomarker for enrollment.

Does this trial require MUC16?

Yes, MUC16 CA125 ≤ 35 U/mL is a required biomarker for enrollment.

Is there an age limit?

Yes. Patients must be 80 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify